Altimmune Future Growth
Future criteria checks 2/6
Altimmune is forecast to grow earnings and revenue by 18.6% and 83.2% per annum respectively. EPS is expected to grow by 28.3% per annum. Return on equity is forecast to be -48.2% in 3 years.
Key information
18.6%
Earnings growth rate
28.3%
EPS growth rate
| Biotechs earnings growth | 42.6% |
| Revenue growth rate | 83.2% |
| Future return on equity | -48.2% |
| Analyst coverage | Good |
| Last updated | 05 Dec 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0 | -176 | -96 | -91 | 8 |
| 12/31/2025 | 25 | -102 | -78 | -8 | 8 |
| 12/31/2024 | 0 | -96 | -78 | -83 | 8 |
| 9/30/2024 | 0 | -104 | -78 | -78 | N/A |
| 6/30/2024 | 0 | -101 | -71 | -71 | N/A |
| 3/31/2024 | 0 | -93 | -73 | -73 | N/A |
| 12/31/2023 | 0 | -88 | -76 | -76 | N/A |
| 9/30/2023 | 0 | -78 | -77 | -77 | N/A |
| 6/30/2023 | 0 | -81 | -71 | -71 | N/A |
| 3/31/2023 | 0 | -85 | -69 | -68 | N/A |
| 12/31/2022 | 0 | -85 | -63 | -63 | N/A |
| 9/30/2022 | 3 | -87 | -67 | -67 | N/A |
| 6/30/2022 | 3 | -97 | -70 | -70 | N/A |
| 3/31/2022 | 4 | -102 | -80 | -72 | N/A |
| 12/31/2021 | 4 | -97 | -91 | -78 | N/A |
| 9/30/2021 | 3 | -84 | -82 | -70 | N/A |
| 6/30/2021 | 6 | -68 | -74 | -61 | N/A |
| 3/31/2021 | 7 | -60 | -54 | -50 | N/A |
| 12/31/2020 | 8 | -49 | -35 | -34 | N/A |
| 9/30/2020 | 6 | -43 | -23 | -23 | N/A |
| 6/30/2020 | 4 | -36 | -16 | -16 | N/A |
| 3/31/2020 | 5 | -22 | -12 | -12 | N/A |
| 12/31/2019 | 6 | -21 | -10 | -10 | N/A |
| 9/30/2019 | 8 | -42 | -13 | -13 | N/A |
| 6/30/2019 | 10 | -34 | -12 | -11 | N/A |
| 3/31/2019 | 11 | -40 | -8 | -8 | N/A |
| 12/31/2018 | 10 | -42 | -10 | -9 | N/A |
| 9/30/2018 | 11 | -29 | -10 | -9 | N/A |
| 6/30/2018 | 13 | -58 | N/A | -12 | N/A |
| 3/31/2018 | 13 | -52 | N/A | -20 | N/A |
| 12/31/2017 | 11 | -51 | N/A | -20 | N/A |
| 9/30/2017 | 9 | -43 | N/A | -17 | N/A |
| 6/30/2017 | 5 | -16 | N/A | -15 | N/A |
| 3/31/2017 | 3 | -14 | N/A | -8 | N/A |
| 12/31/2016 | 3 | -11 | N/A | -6 | N/A |
| 9/30/2016 | 3 | -10 | N/A | -7 | N/A |
| 12/31/2015 | 5 | -7 | N/A | -5 | N/A |
| 12/31/2014 | 6 | -1 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3G0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 3G0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 3G0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 3G0's revenue (83.2% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: 3G0's revenue (83.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3G0 is forecast to be unprofitable in 3 years.